Now Playing
Opinion|Videos|December 20, 2024
ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas
Panelists discuss how exciting new data from ASH 2024 on bispecific therapies for B-cell lymphomas, including epcoritamab in diffuse large B-cell lymphoma, mosunetuzumab in follicular lymphoma, and odronextamab are shaping treatment algorithms by providing long-term follow-up data that could influence therapeutic strategies and patient management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- There is a wealth of exciting data emerging from ASH 2024 on bispecific therapies for B-cell lymphomas. Before we discuss these new findings, which bispecific therapies were already available for B-cell lymphomas? How were they typically positioned within treatment algorithms?
- Let’s discuss some of the long-term data updates being presented. How do the 3-year follow-up data on epcoritamab in DLBCL impact its role in your treatment algorithms?
- 4-year follow-up data for mosunetuzumab in follicular lymphoma were also presented. What are the key insights from these data?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Unexplained Pauses Hit Nearly Half of Monthly-Updated CDC Databases, Raising Transparency Concerns
2
Clinical Trial Data Signal a New Era for Atopic Dermatitis, Melanoma, and Psoriasis
3
CRC Becomes Leading Cause of Cancer-Related Death in Younger Adults, Highlighting Prevention Gaps
4
ACE Inhibitors Linked to Reduced Mortality in Patients with Idiopathic Pulmonary Fibrosis
5
